GlaxoSmithKline Pharmaceuticals share news, announcements and annual reports
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
GlaxoSmithKline Pharmaceuticals Limited · Formerly Glaxo (India) · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1969 on BSE, Dec 2000 on NSE
Last close ₹2,494.30down ₹20.80 (0.83%)BSE ₹2,483.55
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,515.10.
30 Oct: open ₹2,527.60, high ₹2,528.90, low ₹2,479.30
52-week range of traded prices to 30 Oct 2026
₹2,088.10Low, 12 Jun 2026₹3,120.70High, 28 Aug 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹42,255 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.56
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.64
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,34965.0% delivered
GlaxoSmithKline Pharmaceuticals share news and announcements
719 announcements, routine notices left out, newest first. Page 3 of 15.
Mar 2025
28 Mar · Meeting
26 Mar · Management
26 Mar · Board meeting
Feb 2025
28 Feb · Legal
28 Feb · Legal
14 Feb · Board meeting
14 Feb · Results
14 Feb · Board meeting
14 Feb · Business
14 Feb · Results
11 Feb · Analysts
11 Feb · Legal
5 Feb · Legal
5 Feb · Legal
4 Feb
Jan 2025
15 Jan · Board meeting
Not held on this date
6 Jan · Management
6 Jan · Management
Dec 2024
30 Dec · Management
4 Dec · Legal
Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. -2. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Nov 2024
27 Nov
4 Nov
4 Nov · Updates
Oct 2024
29 Oct · Corporate action
29 Oct
29 Oct · Business
29 Oct · Results
24 Oct · Corporate action
24 Oct · Analysts
16 Oct · Legal
Sep 2024
16 Sep · Updates
3 Sep · Updates
3 Sep · Updates
2 Sep · Updates
Aug 2024
31 Aug · Updates
30 Aug · Updates
26 Aug · Updates